Our top pick for
Phreesia, Inc is a health information services business based in the US. Phreesia shares (PHR) are listed on the NYSE and all prices are listed in US Dollars. Phreesia employs 532 staff and has a trailing 12-month revenue of around USD$139.7 million.
|52-week range||USD$16.01 - USD$81.592|
|50-day moving average||USD$67.883|
|200-day moving average||USD$45.6256|
|Wall St. target price||USD$67.36|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-35.448|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Phreesia stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Phreesia's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Phreesia's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Phreesia shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$139.7 million|
|Gross profit TTM||USD$80.1 million|
|Return on assets TTM||-5.58%|
|Return on equity TTM||-12.29%|
|Market capitalisation||USD$2.9 billion|
TTM: trailing 12 months
There are currently 1.7 million Phreesia shares held short by investors – that's known as Phreesia's "short interest". This figure is 0.4% down from 1.7 million last month.
There are a few different ways that this level of interest in shorting Phreesia shares can be evaluated.
Phreesia's "short interest ratio" (SIR) is the quantity of Phreesia shares currently shorted divided by the average quantity of Phreesia shares traded daily (recently around 472649.59128065). Phreesia's SIR currently stands at 3.67. In other words for every 100,000 Phreesia shares traded daily on the market, roughly 3670 shares are currently held short.
However Phreesia's short interest can also be evaluated against the total number of Phreesia shares, or, against the total number of tradable Phreesia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Phreesia's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Phreesia shares in existence, roughly 40 shares are currently held short) or 0.0494% of the tradable shares (for every 100,000 tradable Phreesia shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Phreesia.
Find out more about how you can short Phreesia stock.
We're not expecting Phreesia to pay a dividend over the next 12 months.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform also provides a registration solution to automate patient self-registration; patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and life sciences, pharmaceutical, medical device, and biotechnology companies. Phreesia, Inc. has a strategic alliance agreement with Allscripts Healthcare, LLC. The company was founded in 2005 and is headquartered in New York, New York.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.